Drug Prices on the Stock Exchange and the Collapse of Corporate Mathematics

From the perspective of value tradition inspired by Graham and Buffett, the stock market often confuses price with intrinsic value, allowing pharmaceutical companies to maintain patent monopolies shielded from real competition. By crossing this scenario with the portal's archives, we note an obvious parallel with Dell's recent stock rally and heavyweight corporate balance sheets: the market applauds high margins without weighting the imminent regulatory and political risk that can destroy this thesis overnight. The lack of effective competition transforms medical patents into lifetime rents guaranteed by consumer despair, annihilating the margin of safety essential for the long-term investor who values capital integrity.

The structural causes of this distortion include market concentration and dependence on global supply chains tied to exchange rate variations, where the inattentive investor ends up financing unsustainable operating margins. With the Selic rate maintained at contractionary levels of 14.00% per year, any pricing error in risk assets or the bursting of a sector bubble can generate a severe domino effect on the Brazilian and international stock exchanges. Each inflated quotation of global laboratories carries the latent risk of severe corrections when governments begin to intervene aggressively in drug price control, invalidating optimistic projections from Wall Street analysts.

For the 30-day horizon, the probability is medium for occasional volatilities in the healthcare sector due to regulatory pressures in the United States and Europe, indirectly affecting global funds traded on B3. In the 90-day horizon, with high probability, the market is expected to start pricing in the exhaustion of debt capacity.